This white paper summarizes the current consensus of the Reproductive Subcommittee of the Oligonucleotide Safety Working Group on strategies to assess potential reproductive and/or developmental toxicities of therapeutic oligonucleotides (ONs). The unique product characteristics of ONs require considerations when planning developmental and reproductive toxicology studies, including (a) chemical characteristics, (b) assessment of intended and unintended mechanism of action, and (c) the optimal exposure, including dosing regimen. Because experience across the various classes of ONs as defined by their chemical backbone is relatively limited, best practices cannot be defined. Rather, points to consider are provided to help in the design of science-based reproductive safety evaluation programs based upon product attributes.
Get full access to this article
View all access options for this article.
References
1.
CavagnaroJA (2008) The principles of ICH S6 and Yoach. In: Preclinical Safety Evaluation of Biopharmaceuticals: A Science-based Approach to Facilitating Clinical Trials. CavagnaroJA, ed. John Wiley & Sons, NJ, pp. 45–65.
2.
BlackLE, FarrellyJG, CavagnaroJA, AhnC-H, DegeorgeJJ and TaylorAS. (1994). Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Devel, 4:299–301.
3.
CavagnaroJA. (2002). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Rev Drug Discov, 1:469–475.
4.
CavagnaroJ. (2010). Considerations in the preclinical development of biopharmaceuticals. In: Comprehensive Toxicology, 2nd ed. Vol. 3: Toxicity Testing and Evaluation. McQueenCA, ed. Elsevier, pp. 29–52.
5.
KornbrustD, CavagnaroJ, LevinA, FoyJ, PavcoP, Gamba-VitaloC and GuimondA. (2013). Oligo Safety Working Group Exaggerated Pharmacology Subcommittee consensus document. Nucleic Acid Ther, 23:21–28.
6.
BermanC, CannonK, CuiY, KornbrustDJ, LagruttaA, SunSZ, TepperJ, WaldronG, and YounisHS. (2014) Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics. Nucleic Acid Ther, 4:291–301.
LermanSA, HewKW, StewartJ, StumpDG and WiseLD. (2009). The nonclinical fertility study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol, 86:429–36.
9.
WiseLD, BuschmannJ, FeustonMH, FisherJE, HewKW, HobermanAM, LermanSA, OoshimaY and StumpDG. (2009). Birth Defects Res B Dev Reprod Toxicol, 86:418–28.
10.
BaileyGP, WiseLD, BuschmannJ, HurttM and FisherJE. (2009). Pre- and postnatal developmental toxicity study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol, 86:437–45.
HenckJW, HilbishKG, SerabianMA, CavagnaroJA, HendrickxAG, AgnishND, KungAHC and MordentiJ. (1996). Reproductive toxicity testing of therapeutic biotechnology agents. Teratology, 53:185–195.
13.
WeinbauerGF, FuchsA, NiehausM and LuetjensCM. (2011). The enhanced pre- and postnatal study for nonhuman primates: Update and perspectives. Birth Defects Res C Embryo Today, 93:324–333.
14.
ChellmanGJ, BussiereJL, MakoriN, MartinPL, OoshimaY and WeinbauerGF. (2009). Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Res B Dev Reprod Toxicol, 86:446–462.
15.
MartinP, BreslinW, RoccaM, WrightD and CavagnaroJ. (2009). Considerations in assessing the reproductive and developmental toxicity potential of biopharmaceuticals. Birth Defects Res B Dev Reprod Toxicol, 33:176–203.
16.
MartinP and WeinbauerG. (2010). Developmental toxicity testing of biopharmaceuticals in nonhuman primates: Previous experiences and future directions. Int J Toxicology, 29:552–568.
LevinAA and HenrySP. (2008). Toxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities. In: Preclinical Safety Evaluation of Biopharmaceuticals. CavagnaroJA, ed. John Wiley & Sons, NJ, pp. 537–574.
20.
AgrawalS, TemsamaniJ and TangJY. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci, 88:7595–7599.
21.
HenrySP, DennyKH, TemplinMV, YuRZ and LevinAA. (2004). Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res B Dev Reprod Toxicol, 71:359–367.
22.
HenrySP, DennyKH, TemplinMV, YuRZ and LevinAA. (2004). Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res B Dev Reprod Toxicol, 71:368–373.
23.
GaudetteMF, HampikianG, MetelevV, AgrawalS and CrainWR. (1993). Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. Antisense Res Dev, 3:391–397.
24.
SoucyNV, RileyJP, TemplinMV, GearyR, De PeysterA and LevinAA. (2006). Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. Birth Defects Res B Dev Reprod Toxicol, 77:22–28.
25.
DriverSE, RobinsonGS, FlanaganJ, ShenW, SmithLE, ThomasDW and RobertsPC. (1999). Oligonucleotide-based inhibition of embryonic gene expression. Nat Biotechnol, 17:1184–1187.
TreacyG. (2000). Using and analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNF alpha monoclonal antibody. Hum Exp Toxicol, 19:226–228.
28.
BauerS, KirschningCJ, HäckerH, RedeckeV, HausmannS, AkiraS, WagnerH and LipfordGB. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci (USA), 98:9237–9242.
29.
LuiYJ. (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol, 23:275–306.
30.
PraterMR, JohnsonVJ, GermolecDR, LusterMI and HolladaySD. (2006). Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine, 24:263–271.
31.
Scharfe-NugentA, CorrSC, CarpenterSB, KeoghL, DoyleB, MartinC, FitzgeraldKA, DalyS, O'LearyJJ, and O'NeillLA. (2012). TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol, 188:5706–5712.
32.
ThaxtonJE, RomeroR and SharmaS. (2009). TLR-9 activation coupled to IL-10 deficiency induced adverse pregnancy outcomes. J Immunol, 183:1144–1154.
33.
ItoS-I, IshiiKJ, ShirotaH and KlinmanDM. (2004). CpG Oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect Immunity, 72:3543–3548.
34.
BarrierM, Lacroix-LamandeS, MancassolaR, AurayG, BernadetN, ChausseA-M, UematsuS, AkiraS and LaurentF. (2006). Oral and intraperitoneal administration of phosporothioate oligodeoxynucleotides leads to control of Cryptosporidum parvum infection in neonatal mice. JID, 193:1400–1407.
35.
GribarSC, SodhiCP, RichardsonWM, AnandRJ, GittessGK, BrancaMF, JakubA, ShiX, ShahS, OzolekJA, and HackamDJ. (2009). Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol, 182:636–646.
36.
Lacrois-LamandeS, RochereauN, MancassolaR, BarrierM, ClauzonA and LaurentF. (2009). Neonate intestinal immune response to CpG oligonucleotide stimulation. PLoS One, 4:1–8.
37.
LuiY, LiminZ, FathereeNY, LiuX, PachecoSE, TatevianN and RhoadsJM. (2009). Changes in intestinal Toll-like receptors and cytokines precede histological injury in a rat model of necrotizing enterocolitis. Am J Gastrointest Liver PHysiol, 297:G442–G450.
38.
YamaguchiY, HarkerJS, WangB, OpenshawPJ, TregoningJS, and CulleyFJ. (2012). Preexposure to CpG protects against delayed effects of neonatal respiratory syncytial virus infection. J Virol, 86:10456–10461.
39.
KremenchutzkyM, MorrowS and RushC. (2007). The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf, 6:279–288.
40.
Sandberg-WollheimM, FrankD, GoodwinTM, GiesserB, Lopez-BresnahanM, Stam- MoragaM, ChangP and FrancisGS. (2005). Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology, 65:802–806.
41.
De WitD, OlislagersV, GorielyS, VermeulenF, WagnerH, GoldmanM and WillemsF. (2004). Blood plasmacytoid dentritic cell response to CpG oligodeoxynucleotides are impaired in newborns. Blood, 103:1030–1032.
42.
NguyenM, LeuridanE, ZhangT, De WitD, WillemsF, Van DammeP, GoldmanM and GorielyS. (2010). Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One, 5:e10407.
43.
LinY, LiangZ, ChenY and ZengY. (2006). TLR3-involved modulation of pregnancy tolerance in double-stranded RNA-stimulated NOD/SCID mice. J Immunol, 176:4147–4154.
44.
ZhangJ, WeiH, WuD and TianZ. (2007). Toll-like receptor 3 agonist induces impairment of uterine vascular remodeling and fetal loses in CBA x DBA/2 mice. J Repro Immunol, 74:61–67.
45.
KogaK and MorG. (2010) Toll-like recpetors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am J Reprod Immunol, 63:587–600.
46.
ChatterjeeP, WeaverLE, DoerschKM, KoprivaSE, ChiassonVL, AllenSJ, NarayananAM, YoungKJ, JonesKA, KuehlTJ and MitchellBM. (2012). Placental toll-like receptor 3 and toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. Plos ONE, 7:e41884.
47.
SchubertD, LevinA, KornbrustD, BermanCL, CavagnaroJ, HenryS, SequinR, FerrariN and ShrewsburySB. (2012). The Oligonucelotide Safety Working Group (OSWG). Nucleic Acid Ther, 22:211–212.
